Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
Breaking: Catalent
$CTLT to buy Orgenesis'#celltherapy#CDMO biz Masthercell for $315m - story@BioProInsider Insider https://buff.ly/36PRRod pic.twitter.com/gdXg2Jb6nZ
-
Lack of good
#CDMOs a factor for@KrystalBiotech in investing $70-90m into internal PA gene therapy plant https://buff.ly/2Obgc1e pic.twitter.com/wqhhN650eL
-
Ori: Partnerships key to bring down cell therapy COGS - UK firm says its automated closed manufacturing platform can reduce autologous
#celltherapy COGS by 60-80% and has teamed with#CDMO@HCATS_CDMO https://buff.ly/2RUbKoM pic.twitter.com/S7edQXpzFo
-
It's here! Falcon CEO Susan Nichols’ annual roundup of top events within the cell and gene therapy space in 2019, from
@Phacilitate#PLW2020 Contains#CRISPR capacity, and#BigPharma M&A , but#patientaccess takes the top spot https://buff.ly/3aLsBmf pic.twitter.com/yCG1G6X0Wf
-
Discovery Labs' newly formed CDMO in $1.2bn push to deliver capacity to cell & gene space at ex-GSK site in PA - Bioprocess Insider, from
@Phacilitate#plw2020 https://buff.ly/2ROxPoC pic.twitter.com/WaZg8fJc6z
-
received a PR claiming creation of world’s largest cell gene
#cdmo . Seemed pie in the sky but talk at#plw2020 by MLP Ventures founder Brian O’Neill behind project was inspirational and 1.6m sqft PA site could turn industry on its head. Ps he got huge cheer from a full roompic.twitter.com/3WHijiPpar
Prikaži ovu nit -
FDA cell and gene therapy forecast ‘unlikely’ - the opinion from Phacilitate
#PLW2020 as number of commercialized therapeutics falls flat after dynamic 2017 https://buff.ly/2tFZyzK pic.twitter.com/9G029ZUYEv
-
All set for the 6.30am
#phacilitate fun run in miami, and also regretting that final beer last nightpic.twitter.com/k8huc6J08v
Prikaži ovu nit -
@BioProInsider and@BioProcessIntl all set for the plenary at#phacilitate2020 chaired by the legendary@ADaviesDHCG (though he’s a bit of a Dark Horse)pic.twitter.com/Ze5U6VnsMM
-
$IOVA iovance admits TIL therapies with 22 day manufacturing process and potential gene editing added will be very expensive, though refuses to say whether it will be Kymriah expensive or Zolgensma expensive, at#phacilitatepic.twitter.com/MePyouHcRD
-
@ADaviesDHCG talks to Joan Finnegan,#cysticfibrosis advocate, about the patient side of the pharma and regenerative med industry in emotional fireside chat. Too often patients are overlooked at industry conferences but not at#phacilitatepic.twitter.com/bxgWFQWaFm
-
The tech of tomorrow zone at
#phacilitate2020 sponsored by @BioProcessIntl and @BioProInsider is shaping up nicely... looking forward to a great showpic.twitter.com/hGA8ZaRSzw
-
Takeda to Fund AI Projects at MIT as Part of New 3-Year Collaboration https://buff.ly/2QytIgX via
@xconomypic.twitter.com/YLWdymGrFq
-
How process optimization brought Bivigam back - ADMA Biologics says a data driven approach was key to bringing its primary immune deficiency disease drug Bivigam back to market https://buff.ly/39AXtp4 pic.twitter.com/vSreZK8Mtz
-
Healthcare
#AI Tech is Here, Now We Must Learn to Manage the Data https://buff.ly/34Op4PT via@xconomypic.twitter.com/WfWOlFD6ci
-
Evotec CEO Discusses Ways to Make Drug R&D Faster and Better https://buff.ly/2ZhWRjq via
@xconomypic.twitter.com/iWnHMIZLr4
-
On the first day of Christmas my leading
#bioprocess news site gave to me, a merger based on CAR-T... Check out@BioProInsider festive look back at 2019 https://buff.ly/374OHxn pic.twitter.com/wdS42W6AA1
-
Oxford Biomedica will keep supplying
@Novartis with the vectors needed to make Kymriah and other CAR-T products under a 5-year deal extension https://buff.ly/2M9ZgHC pic.twitter.com/9iuFXZJSM9
-
Hemophilia A-OK! Roche’s $4.3bn Spark buy - There is no risk of competitive harm between Roche’s approved hemophila A monoclonal antibody and Spark’s
#genetherapy candidates, says@FTC https://buff.ly/2M1FFJl pic.twitter.com/vzVqW3JWIT
-
a
@BioProInsider exclusive: WuXi Biologics establishes microbial fermentation platform after building up mammalian and#vaccine services - https://buff.ly/34qbAd9 pic.twitter.com/lNdzu2omod
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.